Showing 2141-2150 of 5771 results for "".
- Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19https://modernod.com/news/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19/2477489/Johnson & Johnson announced a $1 billion deal with the U.S. government to create enough manufacturing capacity to make more than 1 billion doses of a potential vaccine for COVID-19. Johnson & Johnson said on Monday it has been working on a vaccine since January 2020 and expects to initiat
- Sight Sciences Announces Publication of Historical Review of Canal Surgeryhttps://modernod.com/news/sight-sciences-announces-publication-of-historical-review-of-canal-surgery/2477484/Sight Sciences announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, PhD, and Reay Brown, MD, has been published in
- NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.comhttps://modernod.com/news/novabay-pharmaceuticals-announces-the-availability-of-kn95-disposable-masks-on-avenova-com/2477457/NovaBay Pharmaceuticals announced the availability of KN95 disposable air filter masks on the company’s website
- CMS Announces Relief for Clinicians, Providers, Hospitals and Facilities Participating in Quality Reporting Programs in Response to COVID-19https://modernod.com/news/cms-announces-relief-for-clinicians-providers-hospitals-and-facilities-participating-in-quality-reporting-programs-in-response-to-covid-19/2477433/On Sunday, The Centers for Medicare & Medicaid Services (CMS) announced relief for the clinicians, providers, and facilities participating in Medicare quality reporting programs, including the 1.2 million clinicians in the Quality Payment Program and on the front lines of America’s fight agai
- Vit-Buckle Society Annual Meeting Cancelledhttps://modernod.com/news/vit-buckle-society-annual-meeting-cancelled/2477432/The Board of Trustees and the Executive Committee of the Vit-Buckle Society (VBS) said that its annual meeting, originally scheduled for March 26-28 in Miami, has been officially cancelled, according to a email sent to its members on Friday. Previously, the meeting was designated as postposed.
- Topcon Announces Customer Initiatives to Combat Global COVID-19 Crisishttps://modernod.com/news/topcon-announces-customer-initiatives-to-combat-global-covid-19-crisis/2477421/As the COVID-19 pandemic continues to escalate across the globe, Topcon Healthcare has announced a series of initiatives and programs designed to support its customers during this time of unprecedented challenges. As healthcare providers, eye doctors are required to be in close contact wit
- Sight Sciences Announces $30 Million Financinghttps://modernod.com/news/sight-sciences-announces-30-million-financing/2477405/Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMN
- ASCRS Officially Cancels Its Annual Meetinghttps://modernod.com/news/ascrs-officially-cancels-its-annual-meeting/2477401/The American Society of Cataract and Refractive Surgery (ASCRS) is cancelling its annual meeting originally scheduled for May 15-20 in Boston. Through a statement po
- Vision Innovation Partners Announces Suspension of Most Office Services, Warby Parker Informs Customers of Store Closures for Two Weeks Due to Coronavirushttps://modernod.com/news/vision-innovation-partners-announces-suspension-of-most-office-services-warby-parker-informs-customers-of-store-closures-for-two-weeks-due-to-coronavirus/2477399/Two vision care businesses are among the first groups in the U.S. to announce that they will be instituting closures of their offices and store networks to prevent the spread of the coronavirus (COVID-19), according to a VisionMonday
- AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsiahttps://modernod.com/news/agtc-announces-completion-of-enrollment-in-all-adult-dose-groups-of-its-ongoing-phase-1-2-clinical-trials-in-patients-with-achromatopsia/2477389/Applied Genetic Technologies Corporation (AGTC) announced that it has completed the planned enrollment in all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its phase 1/2 clinical programs with achromatopsia due to mutation in the